Lifecore Biomedical, Inc. ( (LFCR) ) has released its Q3 earnings. Here is a breakdown of the information Lifecore Biomedical, Inc. presented to its investors.
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, with a notable expertise in manufacturing injectable-grade hyaluronic acid.
In its third quarter fiscal 2025 financial report, Lifecore Biomedical announced revenues of $35.2 million and highlighted strategic developments including signing multiple new agreements with both new and existing customers, as well as strengthening its balance sheet through the sale of excess capital equipment.
Key financial metrics revealed a slight decrease in quarterly revenues by 2% compared to the previous year, primarily due to reduced CDMO revenues. Gross profit also declined by $2.0 million, reflecting inventory adjustments and customer terminations. However, the company managed to enhance operational efficiencies and margins, and increased HA manufacturing revenues by $1.0 million due to heightened demand.
The company recorded a net loss of $14.8 million for the quarter, contrasting with a net income of $15.6 million in the same period last year. Despite this, Lifecore’s adjusted EBITDA showed resilience, with a minor decrease to $5.7 million. The company remains committed to its financial guidance for the full fiscal year 2025, expecting revenues between $126.5 million and $130 million.
Looking ahead, Lifecore Biomedical’s management remains optimistic about achieving sustainable profitability, driven by its strategic initiatives and enhanced manufacturing capabilities, positioning the company for future growth in the biopharmaceutical sector.